Executive summary: U.S. Patent No. 7,572,779 protects a narrow treatment method for estrogen-deficient human females using an oral solid dosage unit containing 17β-estradiol-3-acetate, also called estradiol acetate, with acetic acid and no more than 5% moisture. The protected dose range is approximately 0.1 to 10 mg measured as estradiol equivalent. The patent does not broadly cover estradiol products, all estradiol acetate compositions, vaginal delivery, transdermal products, or oral products lacking the specified moisture and acetic-acid limitations. Its commercial relevance was tied principally to oral estradiol acetate hormone-replacement products, including Femtrace. The patent’s nominal 20-year term appears to have ended in the 2020s, subject to the exact effective filing date and any patent-term adjustment.

U.S. Patent 7,572,779: Estradiol Acetate Oral Dosage Patent Scope, Expiration, and Competitive Landscape

What does U.S. Patent 7,572,779 protect?

The patent protects a method of treating a human female with 17β-estradiol deficiency. The method requires oral administration of a solid dosage unit containing all of the following:

Required element	Claim requirement
Patient	Human female
Condition	Deficiency of 17β-estradiol
Route	Oral administration
Dosage form	Solid dosage unit
Active ingredient	17β-estradiol-3-acetate
Dose	About 0.1 to about 10 mg as estradiol equivalent
Moisture	No more than 5% of the dosage unit
Stabilizer or inhibitor	Acetic acid
Excipient	Pharmaceutically acceptable carrier

Independent claim 1 is a method-of-treatment claim, not a standalone composition claim. A product does not infringe merely because it contains estradiol acetate. The product must be administered in the claimed clinical setting and satisfy the formulation, dose, moisture, and acetic-acid limitations.

The patent is directed to the use of estradiol acetate as an orally administered estrogen replacement therapy. Estradiol acetate is an ester prodrug of estradiol. The inclusion of acetic acid is intended to inhibit ester hydrolysis and improve the stability of estradiol acetate in the dosage form.

How broad is claim 1 of U.S. Patent 7,572,779?

Claim 1 is technically narrow because it combines multiple limitations that must be present in the same treatment method.

Patient and therapeutic-use limitation

The claim applies to a “human female having a deficiency of 17β-estradiol.” This language focuses on hormone-replacement treatment rather than general estrogen administration. Products administered for contraception, oncology, fertility treatment, or non-deficiency indications may fall outside the literal scope unless the facts establish treatment of an estrogen-deficient female.

The claim does not specify menopause, postmenopause, surgical menopause, osteoporosis, vasomotor symptoms, or vaginal atrophy. Those conditions may be relevant to commercial use, but they are not express claim limitations.

Active-ingredient limitation

The required active ingredient is 17β-estradiol-3-acetate. This is materially different from:

17β-estradiol;
estradiol valerate;
estradiol cypionate;
ethinyl estradiol;
conjugated estrogens;
estetrol;
estriol; and
estrone sulfate.

A generic product containing ordinary estradiol would not literally satisfy the estradiol-acetate limitation. A product containing estradiol valerate would also be chemically distinct.

Dose limitation

The claim covers approximately 0.1 to 10 mg of estradiol acetate expressed as estradiol equivalent. The “as estradiol equivalent” language matters because the labeled mass of estradiol acetate is higher than the corresponding estradiol moiety.

For infringement analysis, the relevant questions include:

The amount of estradiol acetate per dosage unit.
The calculation method used to determine estradiol equivalent.
Whether the amount falls within the “about 0.1 to about 10 mg” range.
Whether the dosage is administered as one claimed solid unit or through a regimen outside the claim.

A product below or above the claimed range may avoid literal infringement, although the scope of “about” and the doctrine of equivalents could become disputed issues.

Moisture limitation

The dosage unit must have a moisture content of no more than 5%. This limitation applies to the dosage unit, not merely to the active ingredient or an excipient.

The patent does not, on the face of the supplied claims, specify the analytical method for measuring moisture. In litigation, the parties could dispute whether moisture means:

total water content;
loss on drying;
Karl Fischer water measurement;
residual moisture at manufacture; or
moisture at the time of administration.

The moisture requirement creates a significant product-specific limitation. A competing formulation could contain estradiol acetate and acetic acid but avoid infringement if its dosage unit exceeds the claimed threshold, although that approach could create stability, manufacturing, or shelf-life problems.

Acetic-acid limitation

The dosage unit must contain acetic acid as a pharmaceutically acceptable inhibitor of ester hydrolysis. This is one of the most important claim limitations.

The claim does not cover every stabilizer used with estradiol acetate. It specifically requires acetic acid. Other acids or stabilizers, such as citric acid, tartaric acid, ascorbic acid, or buffering agents, would not literally satisfy this limitation unless acetic acid is also present or an equivalents theory applies.

The claim also requires acetic acid to function as an inhibitor of ester hydrolysis. The role of acetic acid may be relevant if a formulation contains trace acetate or acetic acid incidentally but does not use it as a stabilizing component.

What do claims 2 through 5 add?

The dependent claims narrow claim 1 as follows:

Claim	Additional limitation	Commercial significance
2	One or more additional medicaments	Covers combination products
3	At least one additional medicament has progestational activity	Covers estrogen-progestin hormone therapy
4	Dosage form is a tablet, capsule, powder, lozenge, troche, or suspension	Limits the solid dosage-unit format
5	Dosage form is a tablet or capsule	Most commercially relevant formulation limitation

Claim 2 covers combinations with additional medicaments. Claim 3 is directed specifically to a progestational agent, such as medroxyprogesterone acetate, norethindrone acetate, micronized progesterone, or another progestin.

Claim 4 is internally important because a “suspension” is not ordinarily a solid dosage form in its conventional pharmaceutical meaning. The dependent claim should therefore be read in light of the specification and prosecution history. Claim 5 narrows the dosage form to tablets and capsules and is likely the most relevant dependent claim for an oral hormone-replacement product.

What formulations are protected by U.S. Patent 7,572,779?

The strongest literal infringement scenario would involve a tablet or capsule containing:

estradiol acetate;
acetic acid;
a pharmaceutical carrier;
no more than 5% moisture; and
approximately 0.1 to 10 mg estradiol equivalent.

A formulation could also contain a progestin and potentially fall within claims 2 and 3.

The patent does not require a particular:

tablet weight;
excipient system;
dissolution profile;
particle size;
coating;
packaging configuration;
release mechanism; or
manufacturing process.

Those omissions give the claims some formulation flexibility. The patent nonetheless remains narrower than a conventional composition patent because the claims are framed as treatment methods and require the claimed administration context.

Formulations likely outside the literal claim scope

The following products generally would not satisfy claim 1 without additional facts:

oral estradiol-only products without estradiol acetate;
oral estradiol acetate products without acetic acid;
dosage units containing more than 5% moisture;
transdermal estradiol patches;
estrogen creams, rings, or vaginal tablets;
injectable estradiol acetate;
products administered to males;
products used without a deficiency of 17β-estradiol;
products outside the claimed dose range; and
products in which estradiol acetate is absent from the administered dosage unit.

What is the Orange Book status of U.S. Patent 7,572,779?

The patent’s commercial context is associated with oral estradiol acetate hormone-replacement products, particularly Femtrace, an estradiol acetate product marketed by Warner Chilcott. FDA Orange Book treatment depends on whether the patent was submitted for the relevant approved NDA and whether the listed claims covered the approved product or an approved method of use. FDA’s Orange Book identifies patent and exclusivity information submitted by NDA holders, but Orange Book listing does not establish patent validity or infringement.[1]

The regulatory analysis should distinguish three questions:

Whether U.S. Patent 7,572,779 was listed against the relevant estradiol acetate NDA.
Whether the listed patent remained active when a generic application was filed.
Whether the approved generic labeling included a use covered by the listed method claims.

An Orange Book listing would have been commercially significant during the patent term because an ANDA applicant could have faced a Paragraph IV certification and potential 30-month stay under the Hatch-Waxman framework.[2] After patent expiration, a Paragraph IV challenge would ordinarily lose its practical purpose for that patent, although other listed patents could still affect approval or launch.

When did U.S. Patent 7,572,779 lose exclusivity?

The patent term is governed principally by 35 U.S.C. § 154. For a post-1995 U.S. utility patent, the term generally runs 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, terminal disclaimer, and any applicable patent-term extension.[3]

The issued patent date was August 11, 2009. The nominal expiration date must be calculated from the effective nonprovisional filing date shown in the patent’s front-page bibliographic data, not from the issue date. On the available patent chronology, the nominal term falls in the 2020s and appears to have ended by 2025, subject to any patent-term adjustment recorded by the USPTO.

The patent’s practical exclusivity also depended on:

whether the underlying estradiol acetate product remained marketed;
whether the relevant NDA was active;
whether the patent was listed in the Orange Book;
whether a generic applicant filed an ANDA; and
whether any later formulation or method patents covered the product.

A patent expiration date is not the same as the end of all commercial exclusivity. FDA regulatory exclusivity, orphan-drug exclusivity, pediatric exclusivity, and separate formulation patents can create independent barriers. No claim supplied here establishes a separate regulatory exclusivity period.

Which companies challenged the estradiol acetate patent?

The supplied claims do not establish the identity of any Paragraph IV challenger, ANDA applicant, or patent-litigation defendant. A Paragraph IV certification is an ANDA filing position, not a claim limitation and not evidence that a court found the patent invalid.

For a complete litigation record, the relevant sources are:

FDA Orange Book patent certifications;
FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations;
PACER;
U.S. district court dockets;
Federal Circuit opinions; and
USPTO Patent Center prosecution records.

The absence of a reported appellate opinion would not prove that no district-court dispute, settlement, or confidential ANDA litigation occurred. Conversely, an Orange Book listing would not prove that a Paragraph IV challenge was filed.

What patent litigation and settlement issues are most relevant?

The principal litigation issues would likely have been claim construction and validity rather than ownership of the estradiol molecule itself.

Claim construction issues

Potential disputes include:

the meaning of “about 0.1 to about 10 mg”;
how estradiol equivalent is calculated;
the meaning of “percent moisture”;
the analytical method used to measure moisture;
whether acetic acid must be intentionally added;
whether acetic acid must demonstrably inhibit ester hydrolysis;
whether a suspension can qualify as a solid dosage unit;
whether administration must be for a diagnosed estrogen deficiency; and
whether a combination product satisfies the additional-medicament limitations.

Validity issues

The patent could face conventional validity arguments involving:

anticipation by earlier estradiol acetate formulations;
obviousness based on known oral estrogen therapy and known ester-stability techniques;
written description;
enablement;
indefiniteness of “about” and “therapeutically effective amount”; and
lack of demonstrated technical effect for the acetic-acid and moisture limitations.

The strongest validity question would likely concern whether the combination of estradiol acetate, acetic acid, low moisture, and oral solid dosage form was predictable from the prior art. The strongest infringement defense would likely focus on failure to prove one or more narrow formulation limitations.

No settlement terms should be inferred from the claims. A settlement could have included a licensed launch date, authorized generic rights, or no-admission provisions, but those terms require a specific public agreement or court filing.

How does this patent compare with competing estrogen patents?

Product or technology	Active ingredient or delivery	Relationship to U.S. 7,572,779
Estradiol acetate oral capsule	Estradiol acetate, oral solid dosage	Closest commercial technology
Generic oral estradiol	17β-estradiol	Usually outside the acetate limitation
Estradiol valerate	Estradiol ester, oral or injectable	Chemically distinct ester
Conjugated estrogens	Mixture of estrogenic compounds	Outside the claimed active ingredient
Transdermal estradiol	Estradiol delivered through skin	Outside oral solid dosage limitation
Vaginal estradiol	Local vaginal delivery	Outside the claimed route and dosage form
Estrogen-progestin combination	Estrogen plus progestin	Potentially within claims 2 and 3 only if the estrogen is estradiol acetate and all claim 1 limits are met

The patent therefore had limited blocking power against the broader estrogen-replacement market. Its principal value was product-specific: protecting an oral estradiol acetate formulation with a defined stabilization approach.

How strong is the patent estate for estradiol acetate?

The estate appears stronger against direct copies of the claimed formulation than against substitute estrogen products. Its main strengths are the specific combination of:

estradiol acetate;
acetic acid;
moisture of 5% or less;
oral solid dosage;
estradiol-equivalent dosing; and
treatment of an estrogen-deficient human female.

Its weaknesses are the absence, in the supplied claims, of broader composition, manufacturing, packaging, polymorph, particle-size, dissolution, or controlled-release claims. A competitor could potentially design around the patent by changing the estrogen ester, removing acetic acid, using another delivery route, or developing a formulation outside the moisture or dose range.

Manufacturing know-how may still create practical barriers. Maintaining low moisture, controlling ester hydrolysis, selecting packaging, and validating shelf life can make a technically noninfringing product commercially difficult. Those barriers are not the same as patent rights and would require separate evidence.

What generic launch risks exist?

The generic-launch risk depends on whether an applicant can establish therapeutic equivalence to the reference listed drug and address any remaining Orange Book patents.

The principal scenarios are:

A generic estradiol product launches without infringing this patent because it contains estradiol rather than estradiol acetate.
A generic estradiol acetate product files a Paragraph IV certification and challenges the patent before expiration.
A generic applicant uses a formulation without acetic acid or outside the moisture limitation.
A generic applicant accepts a later launch date under a settlement.
A generic product is delayed by manufacturing, bioequivalence, supply, or regulatory issues rather than patent enforcement.

Because the claims are method claims, label language is important. A generic applicant may attempt a section viii statement or “skinny label” approach if the approved use covered by the patent can be omitted without undermining the product’s remaining approved indications. The feasibility of that strategy depends on the NDA labeling and the scope of the listed method claims.[2]

Is biosimilar risk relevant to U.S. Patent 7,572,779?

No. Biosimilar law does not apply because estradiol acetate is a small-molecule active ingredient, not a biological product regulated under the Public Health Service Act. The relevant competitive pathway is the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a 351(k) biosimilar application.[4]

What is the commercial exposure of the patent?

The patent’s revenue exposure was concentrated in the oral estradiol acetate product protected by the formulation and treatment claims. It did not control the entire estrogen-replacement market.

Commercial exposure depends on:

sales of the reference product during the patent term;
market share of estradiol acetate versus generic estradiol;
availability of alternative estrogen products;
whether an authorized generic existed;
whether the patent was listed and enforceable;
payer substitution; and
the presence of progestin-combination products.

Public revenue estimates should not be attributed to the patent without verified product-level sales data. The patent itself does not disclose product revenue, market share, or settlement economics.

Key Takeaways

U.S. Patent 7,572,779 is a narrow method patent for oral estradiol acetate treatment.
Claim 1 requires estradiol acetate, acetic acid, a solid dosage unit, no more than 5% moisture, and approximately 0.1 to 10 mg estradiol equivalent.
Ordinary oral estradiol, transdermal estradiol, vaginal estrogen, and conjugated estrogens generally fall outside the literal claim scope.
Claims 2 and 3 cover additional medicaments and progestational combinations.
Claim 5 focuses on tablets and capsules, the most commercially relevant forms.
The patent’s nominal term appears to have ended in the 2020s, likely by 2025, subject to the exact USPTO term calculation.
Biosimilar risk is irrelevant; generic risk is governed by the ANDA and Paragraph IV framework.
The patent had product-specific value but did not broadly block competing estrogen therapies.
Moisture measurement, acetic-acid function, dose conversion, and the “about” range are central infringement and validity issues.

FAQs About U.S. Patent 7,572,779

Does an oral estradiol tablet infringe U.S. Patent 7,572,779?

Usually not if it contains 17β-estradiol rather than estradiol acetate. The patent requires 17β-estradiol-3-acetate.

Does estradiol valerate fall within the patent claims?

No, not literally. Estradiol valerate is a different ester from estradiol-3-acetate.

Can a formulation avoid the patent by replacing acetic acid with citric acid?

That may avoid literal infringement of the express acetic-acid limitation, assuming the formulation contains no acetic acid and no equivalent component under the applicable legal test.

Does the patent cover a vaginal estradiol product?

No. The claims require oral administration of a solid dosage unit.

Is a patent expiration date the same as FDA exclusivity expiration?

No. Patent term, Orange Book listing, FDA regulatory exclusivity, and market availability are separate issues.

Sources

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications. FDA, Center for Drug Evaluation and Research.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
United States Code. (2024). 42 U.S.C. § 262(k): Licensure of biological products as biosimilar or interchangeable.
United States Patent and Trademark Office. (2009). U.S. Patent No. 7,572,779: Patent term and bibliographic record.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002359758	⤷ Start Trial
Canada	2470703	⤷ Start Trial
China	1273141	⤷ Start Trial
China	1564689	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,572,779

Summary for Patent: 7,572,779